- Home
- YCBD vs ENSC Comparison
YCBD vs ENSC Comparison
Compare YCBD & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YCBD
- ENSC
- Stock Information
- Founded
- YCBD 2015
- ENSC 2003
- Country
- YCBD United States
- ENSC United States
- Employees
- YCBD N/A
- ENSC N/A
- Industry
- YCBD Biotechnology: Pharmaceutical Preparations
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- YCBD Health Care
- ENSC Health Care
- Exchange
- YCBD Nasdaq
- ENSC Nasdaq
- Market Cap
- YCBD 7.8M
- ENSC 6.4M
- IPO Year
- YCBD N/A
- ENSC N/A
- Fundamental
- Price
- YCBD $1.49
- ENSC $2.27
- Analyst Decision
- YCBD Strong Buy
- ENSC
- Analyst Count
- YCBD 1
- ENSC 0
- Target Price
- YCBD $2.00
- ENSC N/A
- AVG Volume (30 Days)
- YCBD 11.0M
- ENSC 151.0K
- Earning Date
- YCBD 08-14-2025
- ENSC 11-11-2025
- Dividend Yield
- YCBD N/A
- ENSC N/A
- EPS Growth
- YCBD N/A
- ENSC N/A
- EPS
- YCBD N/A
- ENSC N/A
- Revenue
- YCBD $19,026,064.00
- ENSC $7,413,722.00
- Revenue This Year
- YCBD $0.37
- ENSC N/A
- Revenue Next Year
- YCBD $4.95
- ENSC $1,354.55
- P/E Ratio
- YCBD N/A
- ENSC N/A
- Revenue Growth
- YCBD N/A
- ENSC 415.58
- 52 Week Low
- YCBD $0.59
- ENSC $1.62
- 52 Week High
- YCBD $6.54
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- YCBD 72.63
- ENSC 49.67
- Support Level
- YCBD $0.60
- ENSC $2.35
- Resistance Level
- YCBD $1.94
- ENSC $2.63
- Average True Range (ATR)
- YCBD 0.23
- ENSC 0.19
- MACD
- YCBD 0.07
- ENSC 0.01
- Stochastic Oscillator
- YCBD 64.18
- ENSC 27.88
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.